Hyderabad based CDMO company that offers services to leading global pharmaceutical and fine chemical majors in their NCE development endeavours. From process research & development to late-stage clinical and commercial manufacturing we are committed to provide customers with products fulfilling customer needs and expectations.
Financial Results:
Suven Pharmaceuticals Ltd reported Revenues for Q3FY25 of ₹307.00 Crores up from ₹220.00 Crore year on year, a rise of 39.55%.
Total Expenses for Q3FY25 of ₹212.00 Crores up from ₹169.00 Crores year on year, a rise of 25.44%.
Consolidated Net Profit of ₹83.00 Crores up 76.6% from ₹47.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹3.26, up 77.17% from ₹1.84 in the same quarter of the previous year.
![](data:image/svg+xml;charset=utf-8,<svg height="781px" width="640px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
